Gene: ERBB2

2064
CD340|HER-2|HER-2/neu|HER2|MLN 19|NEU|NGL|TKR1
erb-b2 receptor tyrosine kinase 2
protein-coding
17q12
Ensembl:ENSG00000141736 MIM:164870 Vega:OTTHUMG00000179300 UniprotKB:P04626
NG_007503.1
PubMed
0   ANCO-SNPs
ND|AD
35   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.873e-1 (AD)  7.893e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CPT20.869
SLC16A90.865
NPAS30.863
LRP100.857
PBXIP10.856
PLCD10.855
WLS0.854
ACACB0.85
STK330.848
MRVI10.848

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
AGMAT-0.448
KCNS3-0.426
TYRP1-0.423
MCHR1-0.419
SULT2B1-0.417
ABCC12-0.414
QRFPR-0.413
ZNF385D-0.406
LGI2-0.398
ADRA1D-0.397

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00072TrastuzumabBiotechDrug180288-69-1Approved|InvestigationalTarget
DB01259LapatinibSmall Molecule231277-92-2Approved|InvestigationalTarget
DB04988IGN311BiotechDrug-InvestigationalTarget
DB05773Trastuzumab emtansineBiotechDrug1018448-65-1Approved|InvestigationalTarget
DB05944VarlitinibSmall Molecule845272-21-1InvestigationalTarget
DB06021AV-412Small Molecule451493-31-5InvestigationalTarget
DB06366PertuzumabBiotechDrug380610-27-5ApprovedTarget
DB08916AfatinibSmall Molecule850140-72-6ApprovedTarget
DB11652TucatinibSmall Molecule937263-43-9InvestigationalTarget
DB11973TesevatinibSmall Molecule781613-23-8InvestigationalTarget
DB12267BrigatinibSmall Molecule1197953-54-0Approved|InvestigationalTarget
ID Drug Name Action PubMed
C0264861,2,5,6-dibenzanthracene"1,2,5,6-dibenzanthracene results in decreased expression of ERBB2 mRNA"16269432
C0493251,2-dithiol-3-thione"1,2-dithiol-3-thione results in increased expression of ERBB2 mRNA"19162173
C0284741,4-bis(2-(3,5-dichloropyridyloxy))benzene"CTNNB1 gene mutant form affects the susceptibility to [1,4-bis(2-(3,5-dichloropyridyloxy))benzene affects the expression of ERBB2 protein]"21705713
C0337291H,1H,2H,2H-perfluorodecanol"1H,1H,2H,2H-perfluorodecanol results in decreased expression of ERBB2 mRNA"16393665
C5084061H,1H,2H,2H-perfluorooctan-1-ol"1H,1H,2H,2H-perfluorooctan-1-ol results in decreased expression of ERBB2 mRNA"16393665
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"ERBB2 gene mutant form promotes the reaction [PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine]"20453058
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"20453058
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"[ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased phosphorylation of AKT1 protein"20453058
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"[ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased phosphorylation of EIF4EBP1 protein"20453058
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"[ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased phosphorylation of FOXO1 protein"20453058
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"[ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased phosphorylation of GSK3B protein"20453058
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"[ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased phosphorylation of RPS6KB1 protein"20453058
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"[ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased phosphorylation of RPS6 protein"20453058
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"[ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in increased cleavage of PARP1 protein"20453058
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"PIK3CA gene mutant form promotes the reaction [ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine]"20453058
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"PTEN gene mutant form promotes the reaction [ERBB2 gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine]"20453058
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of ERBB2 mRNA"19114083
C0859112-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Cisplatin]21712253
C0859112-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Doxorubicin]21712253
C0859112-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]21712253
C0859112-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Fluorouracil]21712253
C0859112-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Mitoxantrone]21712253
C0859112-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Paclitaxel]21712253
C0859112-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in increased expression of ABCG2 mRNA]21712253
C0859112-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in increased expression of ABCG2 protein]21712253
C0859112-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]]12439862
C0237042-acetamidoethanethiol2-acetamidoethanethiol analog results in decreased activity of and results in decreased phosphorylation of ERBB2 protein20058253
C0495842-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine"2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of ERBB2 mRNA"8603490
C0546493-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol"3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in decreased expression of ERBB2 mRNA"12734338
C0163923,3'-diindolylmethane"3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased phosphorylation of and results in decreased activity of ERBB2 protein]"16580691
C0163923,3'-diindolylmethane"3,3'-diindolylmethane results in decreased phosphorylation of and results in decreased activity of ERBB2 protein"16580691
C4340033-(4-methylphenylsulfonyl)-2-propenenitrile3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Cisplatin]21712253
C4340033-(4-methylphenylsulfonyl)-2-propenenitrile3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Doxorubicin]21712253
C4340033-(4-methylphenylsulfonyl)-2-propenenitrile3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]21712253
C4340033-(4-methylphenylsulfonyl)-2-propenenitrile3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Fluorouracil]21712253
C4340033-(4-methylphenylsulfonyl)-2-propenenitrile3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Mitoxantrone]21712253
C4340033-(4-methylphenylsulfonyl)-2-propenenitrile3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Paclitaxel]21712253
C4340033-(4-methylphenylsulfonyl)-2-propenenitrile3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in increased expression of ABCG2 mRNA]21712253
C4340033-(4-methylphenylsulfonyl)-2-propenenitrile3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in increased expression of ABCG2 protein]21712253
C4967514-(1H-imidazol-1-yl)retinoic acid4-(1H-imidazol-1-yl)retinoic acid results in decreased expression of ERBB2 protein17145897
C4339384557 W4557 W results in decreased activity of ERBB2 protein17093206
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERBB2 mRNA"27188386
C0275764-hydroxy-2-nonenal4-hydroxy-2-nonenal results in decreased expression of ERBB2 mRNA12419474
C0415944-nonylphenol4-nonylphenol results in decreased expression of ERBB2 mRNA16393665
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERBB2 mRNA"27188386
C000601052(6,7-dimethoxyquinolin-4-yl)(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)methyl acetate"(6,7-dimethoxyquinolin-4-yl)(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)methyl acetate results in decreased expression of ERBB2 protein"25976766
C1078756-(methylamino)pyrido(3,4-d)pyrimidine"6-(methylamino)pyrido(3,4-d)pyrimidine results in decreased activity of ERBB2 protein"15572027
C0207389,10-dihydro-9,10-dihydroxybenzo(a)pyrene"9,10-dihydro-9,10-dihydroxybenzo(a)pyrene results in decreased expression of ERBB2 mRNA"26238291
D000079AcetaldehydeAcetaldehyde affects the expression of ERBB2 mRNA22634333
D000082AcetaminophenAcetaminophen results in decreased expression of ERBB2 mRNA21420995
D000082Acetaminophen[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA25607892
D020106AcrylamideAcrylamide analog results in decreased phosphorylation of ERBB2 protein10753475
D020106AcrylamideAcrylamide results in decreased expression of ERBB2 mRNA28959563
D017500Adenovirus E1A ProteinsAdenovirus E1A Proteins analog results in decreased expression of ERBB2 protein19523934
C550911ado-trastuzumab emtansineado-trastuzumab emtansine binds to and affects the localization of ERBB2 protein20730488
C550911ado-trastuzumab emtansineado-trastuzumab emtansine binds to ERBB2 protein24035823
C550911ado-trastuzumab emtansineado-trastuzumab emtansine binds to ERBB2 protein24035823
C016601afimoxifeneafimoxifene inhibits the reaction [beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]]12439862
C016601afimoxifeneafimoxifene inhibits the reaction [Estrogens results in decreased expression of ERBB2 mRNA]21233418
C016601afimoxifeneERBB2 results in decreased susceptibility to afimoxifene21233418
C016601afimoxifeneafimoxifene results in increased expression of ERBB2 mRNA17640349
C081020AG-879[tyrphostin AG 1478 co-treated with AG-879] results in decreased phosphorylation of ERBB2 protein18618485
D000393Air PollutantsAir Pollutants analog results in decreased expression of ERBB2 mRNA21757418
D000584AmilorideAmiloride results in decreased phosphorylation of ERBB2 protein16059913
D000643Ammonium ChlorideAmmonium Chloride affects the expression of ERBB2 mRNA16483693
D000726Androgen Antagonists[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA25607892
D000880AnthraquinonesAnthraquinones analog results in decreased activity of ERBB2 protein27473261
D000970Antineoplastic AgentsAntineoplastic Agents results in decreased expression of ERBB2 protein23125191
D000970Antineoplastic AgentsAntineoplastic Agents results in decreased expression of ERBB2 protein modified form23125191
D047310Apigenin[Apigenin co-treated with Fluorouracil] results in decreased expression of ERBB2 protein19885610
D017638Asbestos, Crocidolite"Asbestos, Crocidolite results in decreased expression of ERBB2 protein"15626777
D001241AspirinAspirin results in decreased expression of ERBB2 mRNA19424877
D001241AspirinAspirin results in decreased expression of ERBB2 protein19424877
D001241AspirinAspirin results in increased expression of ERBB2 mRNA20457246
C030935benz(a)anthracenebenz(a)anthracene results in decreased expression of ERBB2 mRNA21635667
C022921benzo(k)fluoranthenebenzo(k)fluoranthene results in decreased expression of ERBB2 mRNA21635667
D053119BenzophenanthridinesBenzophenanthridines analog results in decreased expression of ERBB2 mRNA23117580
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of ERBB2 mRNA16269432|2231617
D001564Benzo(a)pyreneBenzo(a)pyrene promotes the reaction [AHR protein binds to ERBB2 promoter]19654925
C072553benzyloxycarbonylleucyl-leucyl-leucine aldehydebenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Quercetin results in decreased expression of ERBB2 protein]18655187
C072553benzyloxycarbonylleucyl-leucyl-leucine aldehydebenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of ERBB2 protein]20332299
C072553benzyloxycarbonylleucyl-leucyl-leucine aldehydebenzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ERBB2 protein20332299
D004958Estradiol[Cycloheximide co-treated with Estradiol] results in decreased expression of ERBB2 mRNA15072547
D004958EstradiolEstradiol promotes the reaction [resveratrol results in increased expression of ERBB2 protein]16488535
D004958EstradiolEstradiol results in decreased expression of ERBB2 mRNA15072547|1639366
D004958EstradiolEstradiol results in decreased expression of ERBB2 protein16488535
D004958EstradiolEstradiol results in increased expression of ERBB2 mRNA17555868
D004958Estradiol[ERBB2 protein co-treated with ERBB3 protein] results in increased susceptibility to Estradiol19861407
D004958EstradiolEstradiol results in increased expression of ERBB2 mRNA17640349
C023888beta-hexachlorocyclohexane2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]]12439862
C023888beta-hexachlorocyclohexaneafimoxifene inhibits the reaction [beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]]12439862
C023888beta-hexachlorocyclohexanebeta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]12439862
C023888beta-hexachlorocyclohexanebeta-hexachlorocyclohexane results in increased activity of ERBB2 protein11222871|9443065
C023888beta-hexachlorocyclohexanebeta-hexachlorocyclohexane results in increased expression of ERBB2 protein12948864
C023888beta-hexachlorocyclohexanebeta-hexachlorocyclohexane results in increased expression of ERBB2 mRNA17640349
C006780bisphenol Abisphenol A results in increased expression of ERBB2 mRNA29275510
C006780bisphenol Abisphenol A results in decreased expression of ERBB2 mRNA26063408
C006780bisphenol Abisphenol A results in increased phosphorylation of ERBB2 protein21988766
C006780bisphenol Abisphenol A affects the expression of ERBB2 mRNA25181051
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA25607892
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERBB2 mRNA28628672
D000069286BortezomibBortezomib promotes the reaction [lapatinib results in decreased phosphorylation of ERBB2 protein]20701607
D000069286BortezomibBortezomib results in decreased phosphorylation of ERBB2 protein20701607
D000069286Bortezomiblapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein]20701607
C471992bosutinibbosutinib results in decreased phosphorylation of ERBB2 protein18385429
D020122tert-Butylhydroperoxidetert-Butylhydroperoxide results in decreased expression of ERBB2 mRNA15336504
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA25607892
C018475butyraldehydebutyraldehyde results in decreased expression of ERBB2 mRNA26079696
C035000CAF protocolERBB2 protein affects the susceptibility to CAF protocol18390970
C420268CanertinibCanertinib inhibits the reaction [EGF protein results in increased phosphorylation of ERBB2 protein]18927496
D002211CapsaicinCapsaicin affects the expression of ERBB2 mRNA19502594
D002211CapsaicinCapsaicin results in decreased expression of ERBB2 protein19855437
D002220CarbamazepineCarbamazepine results in decreased expression of ERBB2 mRNA17147113
D002220CarbamazepineCarbamazepine results in decreased expression of ERBB2 protein16965676
D002220CarbamazepineCarbamazepine results in increased degradation of and results in decreased expression of ERBB2 protein17147113
D002220CarbamazepineCarbamazepine affects the expression of ERBB2 mRNA22634333
C083924CEF regimenERBB2 protein affects the susceptibility to CEF regimen16707747
D002738ChloroquineChloroquine results in decreased expression of ERBB2 protein20332299
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ERBB2 mRNA20938992
C074702chromium hexavalent ionchromium hexavalent ion affects the expression of ERBB2 mRNA18053681
D003024ClozapineClozapine affects the phosphorylation of ERBB2 protein26961615
C034456CMF regimenERBB2 protein affects the susceptibility to [Epirubicin co-treated with CMF regimen]18768436
C018021cobaltous chloridecobaltous chloride results in decreased expression of ERBB2 mRNA19376846
D003300CopperCopper results in decreased expression of ERBB2 mRNA26293553
D003300CopperCopper deficiency results in increased expression of ERBB2 mRNA26033743
D019327Copper SulfateCopper Sulfate results in decreased expression of ERBB2 mRNA19549813
D003375Coumestrol[Coumestrol co-treated with resveratrol] results in decreased expression of ERBB2 mRNA19167446
C477330CP-654577CP-654577 results in decreased activity of ERBB2 protein12907618
C477330CP-654577CP-654577 results in decreased phosphorylation of ERBB2 protein12907618
C516694cruentaren Acruentaren A results in decreased expression of ERBB2 protein24450340
C030973cupric oxidecupric oxide results in decreased expression of ERBB2 mRNA22077320
D003471CuprizoneCuprizone affects the expression of ERBB2 mRNA27523638
D003471CuprizoneCuprizone results in increased expression of ERBB2 mRNA26577399
D003474CurcuminCurcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Doxorubicin]25866362
D003474CurcuminCurcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Etoposide]25866362
D003474CurcuminCurcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Paclitaxel]25866362
D003474CurcuminCurcumin analog promotes the reaction [Cycloheximide results in increased degradation of ERBB2 protein]25866362
D003474CurcuminCurcumin analog results in decreased expression of ERBB2 mRNA17041101|2640932
D003474CurcuminCurcumin analog results in decreased expression of ERBB2 protein17041101|2586636
D003474CurcuminCurcumin analog results in increased degradation of ERBB2 protein25866362
D003474CurcuminCurcumin promotes the reaction [Fluorouracil results in decreased phosphorylation of and results in decreased expression of and results in decreased activity of ERBB2 protein]17918158
D003474CurcuminCurcumin promotes the reaction [Folfox protocol results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB2 protein]17918158
D003474CurcuminCurcumin results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB2 protein17918158
D003474CurcuminCurcumin results in decreased expression of ERBB2 mRNA17041101|1871936
D003474CurcuminCurcumin results in decreased expression of ERBB2 protein17041101|1871936
D003474CurcuminERBB2 protein results in increased susceptibility to Curcumin analog25866362
D003474Curcumin[ERBB2 protein results in increased susceptibility to Curcumin analog] which results in decreased phosphorylation of AK1 protein25866362
D003474Curcumin[ERBB2 protein results in increased susceptibility to Curcumin analog] which results in decreased phosphorylation of MAPK1 protein25866362
D003474Curcumin[ERBB2 protein results in increased susceptibility to Curcumin analog] which results in decreased phosphorylation of MAPK3 protein25866362
D003474CurcuminCurcumin results in decreased expression of ERBB218462866
D003513CycloheximideCurcumin analog promotes the reaction [Cycloheximide results in increased degradation of ERBB2 protein]25866362
D003513Cycloheximide[Cycloheximide co-treated with Estradiol] results in decreased expression of ERBB2 mRNA15072547
D003513CycloheximideCycloheximide results in decreased expression of ERBB2 mRNA15072547|1522809
D003513CycloheximideCycloheximide results in decreased expression of ERBB2 protein20379846
D003513CycloheximideCycloheximide results in increased degradation of ERBB2 protein25866362
D003513CycloheximidePA2G4 protein promotes the reaction [Cycloheximide results in decreased expression of ERBB2 protein]20379846
D003520CyclophosphamideERBB2 affects the susceptibility to [Doxorubicin co-treated with Cyclophosphamide co-treated with docetaxel]17010609
D003520CyclophosphamideERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with docetaxel]15834928
D003520CyclophosphamideERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with pirarubicin co-treated with Fluorouracil]15940066
D003520CyclophosphamideERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]9816327
D003520CyclophosphamideERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]16446318|1668272
D003520CyclophosphamideERBB2 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Thiotepa co-treated with Carboplatin]16446318
D016572CyclosporineCyclosporine results in decreased expression of ERBB2 mRNA20106945|2556210
D003634DDTDDT results in increased phosphorylation of ERBB2 protein9070211
C017185delphinidindelphinidin results in decreased phosphorylation of ERBB2 protein18618485
D003847Deoxyglucose[Deoxyglucose co-treated with Quercetin] results in increased ubiquitination of ERBB2 protein18655187
D003847DeoxyglucoseDeoxyglucose inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]]18655187
D003907DexamethasoneDexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of ERBB2 mRNA]27941970
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERBB2 mRNA28628672
D016190CarboplatinERBB2 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Thiotepa co-treated with Carboplatin]16446318
D003993Dibutyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA25607892
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of ERBB2 mRNA17379624
D002945Cisplatin2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Cisplatin]21712253
D002945Cisplatin3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Cisplatin]21712253
D002945Cisplatin[Cisplatin co-treated with Fluorouracil] results in decreased expression of ERBB2 mRNA15737843
D002945CisplatinCisplatin results in decreased expression of ERBB2 mRNA27392435
D002945CisplatinERBB2 mRNA results in decreased susceptibility to Cisplatin18337622
D002945CisplatinERBB2 protein affects the susceptibility to Cisplatin10327070
D002945CisplatinERBB2 results in decreased susceptibility to Cisplatin21712253
D002945Cisplatin[ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Cisplatin21712253
D003633Dichlorodiphenyl Dichloroethylene[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA25607892
C036042dicyclohexyl phthalatedicyclohexyl phthalate affects the expression of ERBB2 mRNA26924002
D004051Diethylhexyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA25607892
D004054DiethylstilbestrolDiethylstilbestrol results in increased expression of ERBB2 protein16439099
C024629dimethyl phthalatedimethyl phthalate affects the expression of ERBB2 mRNA26924002
C067311docetaxelERBB2 affects the susceptibility to [Doxorubicin co-treated with Cyclophosphamide co-treated with docetaxel]17010609
C067311docetaxelERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with docetaxel]15834928
C067311docetaxelERBB2 protein results in increased susceptibility to docetaxel15567936
D004317Doxorubicin2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Doxorubicin]21712253
D004317Doxorubicin3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Doxorubicin]21712253
D004317DoxorubicinABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Doxorubicin]21712253
D004317DoxorubicinCurcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Doxorubicin]25866362
D004317DoxorubicinDoxorubicin affects the expression of ERBB2 mRNA15205334
D004317DoxorubicinERBB2 affects the susceptibility to [Doxorubicin co-treated with Cyclophosphamide co-treated with docetaxel]17010609
D004317DoxorubicinERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with docetaxel]15834928
D004317DoxorubicinERBB2 protein affects the susceptibility to Doxorubicin10327070
D004317DoxorubicinERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]9816327
D004317DoxorubicinERBB2 protein promotes the reaction [Doxorubicin results in increased phosphorylation of AKT1 protein]16168102
D004317DoxorubicinERBB2 protein results in decreased susceptibility to Doxorubicin25467193|2586636
D004317DoxorubicinERBB2 results in decreased susceptibility to Doxorubicin21712253
D004317Doxorubicin[ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Doxorubicin21712253
D004317DoxorubicinNFE2L2 protein affects the reaction [ERBB2 protein results in decreased susceptibility to Doxorubicin]25467193
D004317Doxorubicin[TOP2A protein co-treated with ERBB2 protein] results in increased susceptibility to Doxorubicin15486187
D004317DoxorubicinNRG1 protein affects the reaction [Doxorubicin affects the phosphorylation of ERBB2 protein]15833803
D004317DoxorubicinDoxorubicin promotes the reaction [HSP90AA1 protein binds to ERBB2 protein]17308081
D004317DoxorubicinDoxorubicin results in increased expression of ERBB2 protein17308081
D004317DoxorubicinERBB2 protein promotes the reaction [NRG1 protein inhibits the reaction [Doxorubicin results in decreased expression of TNNI3 protein]]19801490
D004317DoxorubicinERBB2 protein promotes the reaction [NRG1 protein inhibits the reaction [Doxorubicin results in decreased expression of TNNT2 protein]]19801490
D000068538DutasterideDutasteride results in increased expression of ERBB2 mRNA17636412
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA25607892
D015251EpirubicinERBB2 protein affects the susceptibility to [Epirubicin co-treated with CMF regimen]18768436
D015251EpirubicinERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]16446318|1668272
C045651epigallocatechin gallateepigallocatechin gallate results in decreased phosphorylation of ERBB2 protein18618485
C109476epoxiconazole[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA25607892
D004967Estrogensafimoxifene inhibits the reaction [Estrogens results in decreased expression of ERBB2 mRNA]21233418
D004967EstrogensEstrogens results in decreased expression of ERBB2 mRNA21233418
D004967EstrogensEstrogens results in increased expression of ERBB2 mRNA14647453
C032773ethyl caffeateethyl caffeate affects the expression of ERBB2 protein24892518
C032773ethyl caffeateethyl caffeate affects the phosphorylation of and affects the activity of ERBB2 protein24892518
D005038EthylnitrosoureaEthylnitrosourea results in increased mutagenesis of ERBB2 gene16651423
D005047Etoposide2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]21712253
D005047Etoposide3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]21712253
D005047EtoposideABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Etoposide]21712253
D005047EtoposideCurcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Etoposide]25866362
D005047EtoposideERBB2 protein affects the susceptibility to Etoposide10327070
D005047EtoposideERBB2 protein results in decreased susceptibility to Etoposide25866362
D005047EtoposideERBB2 results in decreased susceptibility to Etoposide21712253
D005047Etoposide[ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Etoposide21712253
D005047EtoposideEtoposide results in decreased expression of ERBB2 mRNA15228094
C052498FEC protocolERBB2 protein promotes the reaction [TOP2A protein results in increased susceptibility to FEC protocol]16682728
C020748ferrous sulfateferrous sulfate inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]]18655187
C020748ferrous sulfateferrous sulfate inhibits the reaction [Quercetin results in decreased expression of and results in increased ubiquitination of ERBB2 protein]18655187
D005395Fish OilsFish Oils results in decreased activity of ERBB2 protein15867269
D0150732-Acetylaminofluorene2-Acetylaminofluorene results in increased expression of ERBB2 protein11350689
D005472Fluorouracil2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Fluorouracil]21712253
D005472Fluorouracil3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Fluorouracil]21712253
D005472FluorouracilABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Fluorouracil]21712253
D005472Fluorouracil[Apigenin co-treated with Fluorouracil] results in decreased expression of ERBB2 protein19885610
D005472Fluorouracil[Cisplatin co-treated with Fluorouracil] results in decreased expression of ERBB2 mRNA15737843
D005472FluorouracilCurcumin promotes the reaction [Fluorouracil results in decreased phosphorylation of and results in decreased expression of and results in decreased activity of ERBB2 protein]17918158
D005472FluorouracilERBB2 mRNA results in decreased susceptibility to Fluorouracil18337622
D005472FluorouracilERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with pirarubicin co-treated with Fluorouracil]15940066
D005472FluorouracilERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]9816327
D005472FluorouracilERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]16446318|1668272
D005472FluorouracilERBB2 results in decreased susceptibility to Fluorouracil21712253
D005472Fluorouracil[ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Fluorouracil21712253
D005472FluorouracilFluorouracil affects the expression of ERBB2 mRNA15205334
D005472FluorouracilFluorouracil results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB2 protein17918158
C410216Folfox protocolCurcumin promotes the reaction [Folfox protocol results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB2 protein]17918158
C410216Folfox protocolFolfox protocol results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB2 protein17918158
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ERBB2 mRNA20938992
C070081fulvestrantERBB2 affects the susceptibility to fulvestrant24169358
C070081fulvestrantfulvestrant results in increased expression of ERBB2 mRNA15072547
C039281furanfuran results in increased expression of ERBB2 mRNA27387713
C419708gefitinibgefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein]17898861
C419708gefitinibgefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein]17898861
C419708gefitinibgefitinib results in decreased phosphorylation of ERBB2 protein16243822
C001277geldanamycin[geldanamycin binds to HSP90B1 protein] inhibits the reaction [HSP90B1 protein binds to ERBB2 protein]8617772
C001277geldanamycingeldanamycin inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]]18655187
C001277geldanamycingeldanamycin results in decreased expression of and results in increased ubiquitination of ERBB2 protein18655187
C001277geldanamycingeldanamycin results in decreased expression of ERBB2 protein24450340
C001277geldanamycingeldanamycin results in increased degradation of ERBB2 protein11071886|1795951
C001277geldanamycinQuercetin promotes the reaction [geldanamycin results in decreased expression of and results in increased ubiquitination of ERBB2 protein]18655187
C001277geldanamycingeldanamycin results in decreased activity of ERBB2 protein15254267
D005947Glucose[Glucose deficiency co-treated with Quercetin] results in increased ubiquitination of ERBB2 protein18655187
D005947GlucoseGlucose deficiency inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]]18655187
C506645GW2974GW2974 results in decreased activity of ERBB2 protein19352663
C551538GW 583340GW 583340 results in decreased phosphorylation of ERBB2 protein28426875
D006220HaloperidolHaloperidol results in increased expression of and results in increased phosphorylation of ERBB2 protein26961615
D006534Heptachlor EpoxideHeptachlor Epoxide results in increased activity of ERBB2 protein11222871
D006861Hydrogen PeroxideHydrogen Peroxide affects the expression of ERBB2 mRNA20044591
D006861Hydrogen PeroxideHydrogen Peroxide results in decreased expression of ERBB2 mRNA12419474
C475919hydroxytamoxifenhydroxytamoxifen results in decreased expression of ERBB2 mRNA15072547
C041508indeno(1,2,3-cd)pyrene"indeno(1,2,3-cd)pyrene results in decreased expression of ERBB2 mRNA"21635667
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERBB2 mRNA28628672
C051890irinotecanirinotecan affects the expression of ERBB2 mRNA20097248
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERBB2 mRNA28628672
C098607JP8 aviation fuelJP8 aviation fuel results in decreased expression of ERBB2 protein17337753
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of ERBB2 mRNA25961927
C456099KF58333KF58333 results in decreased expression of ERBB2 protein11800023
C490728lapatinibBortezomib promotes the reaction [lapatinib results in decreased phosphorylation of ERBB2 protein]20701607
C490728lapatinibERBB2 protein affects the reaction [lapatinib results in decreased activity of MAPK1 protein]25221644
C490728lapatinibERBB2 protein affects the reaction [lapatinib results in decreased activity of MAPK3 protein]25221644
C490728lapatinibERBB2 protein affects the reaction [lapatinib results in decreased expression of CCND1 protein]25221644
C490728lapatinibERBB2 protein affects the reaction [lapatinib results in decreased expression of MCM7 protein]25221644
C490728lapatiniblapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein]20701607
C490728lapatiniblapatinib results in decreased activity of ERBB2 protein15665275|1719253
C490728lapatiniblapatinib results in decreased expression of ERBB2 protein16091755
C490728lapatiniblapatinib results in decreased phosphorylation of ERBB2 protein20701607|2664360
C490728lapatinib[lapatinib results in decreased susceptibility to lapatinib] which results in increased phosphorylation of ERBB2 protein26643609
C490728lapatiniblapatinib results in decreased phosphorylation of ERBB2 protein20197467
C490728lapatiniblapatinib results in decreased activity of ERBB2 protein16091755
D007854LeadLead results in decreased expression of ERBB2 mRNA19921347
D017705LignansLignans results in decreased expression of ERBB2 protein15897583
D008043Linseed OilLinseed Oil results in decreased expression of ERBB2 mRNA19904759
D008043Linseed OilLinseed Oil results in decreased expression of ERBB2 protein19904759
D008043Linseed OilLinseed Oil results in decreased phosphorylation of ERBB2 protein19904759
D008043Linseed OilLinseed Oil results in decreased expression of ERBB2 protein21138602
D008043Linseed OilLinseed Oil results in decreased phosphorylation of ERBB2 protein21138602
D008044Linuron[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA25607892
D009637MasoprocolMasoprocol inhibits the reaction [IGF1 protein results in increased phosphorylation of ERBB2 protein]18645000
D008466MechlorethamineMechlorethamine results in decreased expression of ERBB2 protein17932452
D015122MercaptopurineMercaptopurine results in decreased expression of ERBB2 mRNA23358152
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ERBB2 mRNA20938992
D008727MethotrexateERBB2 protein affects the susceptibility to Methotrexate10327070
D008727MethotrexateMethotrexate results in increased expression of ERBB2 mRNA21678067
D008769MethylnitronitrosoguanidineMethylnitronitrosoguanidine results in increased expression of ERBB2 mRNA12634122
D008942Mitoxantrone2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Mitoxantrone]21712253
D008942Mitoxantrone3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Mitoxantrone]21712253
D008942MitoxantroneABCG2 mutant form inhibits the reaction [ERBB2 results in decreased susceptibility to Mitoxantrone]21712253
D008942MitoxantroneERBB2 results in decreased susceptibility to Mitoxantrone21712253
D008942Mitoxantrone[ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Mitoxantrone21712253
C406082monomethylarsonous acidmonomethylarsonous acid results in increased phosphorylation of ERBB2 protein17093206
C517284monomethyl phthalatemonomethyl phthalate affects the expression of ERBB2 mRNA26924002
C523799MRK 003MRK 003 results in decreased expression of ERBB2 mRNA21169257
C570404N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide"N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide results in decreased activity of ERBB2 protein"22003817
C000621033napabucasinnapabucasin results in decreased expression of ERBB2 mRNA25605917
C119536nickel acetatenickel acetate results in increased phosphorylation of ERBB2 protein25053108
D009588Nitrogen Mustard CompoundsNitrogen Mustard Compounds results in decreased expression of ERBB2 mRNA16417271
C562238N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide"ILK protein inhibits the reaction [N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide results in decreased expression of ERBB2 mRNA]"21823616
C562238N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide"ILK protein inhibits the reaction [N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide results in decreased expression of ERBB2 protein]"21823616
C562238N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide"N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide results in decreased expression of ERBB2 mRNA"21823616
C562238N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide"N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide results in decreased expression of ERBB2 protein"21823616
C516714NVP-TAE684[EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein] which results in decreased susceptibility to NVP-TAE68422843788
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB2 mRNA25607892
C440229OleylethanolamideOleylethanolamide promotes the reaction [ERBB2 protein binds to MAP2K1 protein modified form]16269455
C440229OleylethanolamideOleylethanolamide promotes the reaction [ERBB2 protein binds to MAP2K2 protein modified form]16269455
C440229OleylethanolamideOleylethanolamide promotes the reaction [ERBB2 protein binds to MAPK1 protein modified form]16269455
C440229OleylethanolamideOleylethanolamide promotes the reaction [ERBB2 protein binds to MAPK3 protein modified form]16269455
C440229OleylethanolamideOleylethanolamide results in increased phosphorylation of ERBB2 protein16269455
D015525Fatty Acids, Omega-3"Fatty Acids, Omega-3 results in decreased activity of ERBB2 protein"15867269
C507134ON 01910ON 01910 results in increased phosphorylation of ERBB2 protein25472472
C016340o,p'-DDT"o,p'-DDT results in increased activity of ERBB2 protein"11222871|9443065
C055122orlistatERBB2 protein affects the susceptibility to orlistat15870086
C055122orlistatorlistat affects the localization of ERBB2 protein15870086
C055122orlistatorlistat results in decreased expression of ERBB2 mRNA15870086
C055122orlistatorlistat results in decreased expression of ERBB2 protein15870086
D017239Paclitaxel2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Paclitaxel]21712253
D017239Paclitaxel"3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased phosphorylation of and results in decreased activity of ERBB2 protein]"16580691
D017239Paclitaxel3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Paclitaxel]21712253
D017239PaclitaxelCurcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Paclitaxel]25866362
D017239PaclitaxelERBB2 protein affects the susceptibility to Paclitaxel10327070
D017239PaclitaxelERBB2 protein results in decreased susceptibility to Paclitaxel25866362
D017239PaclitaxelERBB2 results in decreased susceptibility to Paclitaxel21712253
D017239Paclitaxel[ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Paclitaxel21712253
D017239PaclitaxelPaclitaxel results in decreased phosphorylation of and results in decreased activity of ERBB2 protein16580691
D017239PaclitaxelERBB2 protein results in decreased susceptibility to Paclitaxel16580691
D010269ParaquatERBB2 protein results in decreased susceptibility to Paraquat25467193
D010269ParaquatNFE2L2 protein affects the reaction [ERBB2 protein results in decreased susceptibility to Paraquat]25467193
D052638Particulate MatterParticulate Matter results in increased expression of ERBB2 mRNA28412507
D020135Peptide Nucleic AcidsPeptide Nucleic Acids results in decreased expression of ERBB2 mRNA16417271
C076994perfluorooctane sulfonic acidperfluorooctane sulfonic acid results in decreased expression of ERBB2 mRNA18692542
C023036perfluorooctanoic acidperfluorooctanoic acid results in decreased expression of ERBB2 protein26879310
D026023PermethrinPermethrin results in increased activity of ERBB2 protein11222871
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERBB2 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of ERBB2 mRNA26272509
C027260pirarubicinERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with pirarubicin co-treated with Fluorouracil]15940066
C410026PKI 166PKI 166 results in decreased activity of ERBB2 protein15377668
D010936Plant ExtractsPlant Extracts results in decreased expression of ERBB2 protein20482751
C045362prochloraz[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA25607892
C035988procymidone[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA25607892
D011441PropylthiouracilPropylthiouracil results in increased expression of ERBB2 mRNA24780913
D011794Quercetinbenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Quercetin results in decreased expression of ERBB2 protein]18655187
D011794Quercetin[Deoxyglucose co-treated with Quercetin] results in increased ubiquitination of ERBB2 protein18655187
D011794QuercetinDeoxyglucose inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]]18655187
D011794Quercetinferrous sulfate inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]]18655187
D011794Quercetinferrous sulfate inhibits the reaction [Quercetin results in decreased expression of and results in increased ubiquitination of ERBB2 protein]18655187
D011794Quercetingeldanamycin inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]]18655187
D011794Quercetin[Glucose deficiency co-treated with Quercetin] results in increased ubiquitination of ERBB2 protein18655187
D011794QuercetinGlucose deficiency inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]]18655187
D011794QuercetinQuercetin inhibits the reaction [EGF protein results in increased phosphorylation of ERBB2 protein]12888923
D011794QuercetinQuercetin inhibits the reaction [TGFA protein results in increased phosphorylation of ERBB2 protein]12888923
D011794QuercetinQuercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]18655187
D011794QuercetinQuercetin promotes the reaction [geldanamycin results in decreased expression of and results in increased ubiquitination of ERBB2 protein]18655187
D011794QuercetinQuercetin promotes the reaction [ST13 protein modified form binds to and results in increased ubiquitination of ERBB2 protein]18655187
D011794QuercetinQuercetin results in decreased expression of and results in decreased phosphorylation of ERBB2 protein12888923
D011794QuercetinQuercetin results in decreased expression of ERBB2 protein15741050
D011794QuercetinQuercetin results in decreased phosphorylation of ERBB2 protein18655187
D011794QuercetinQuercetin results in increased expression of ERBB2 mRNA14715546
D011794QuercetinST13 protein modified form affects the reaction [Quercetin results in increased ubiquitination of ERBB2 protein]18655187
D011794QuercetinQuercetin results in increased ubiquitination of ERBB2 protein21750559
D011799QuinazolinesQuinazolines analog results in decreased phosphorylation of ERBB2 protein10753475
D020849Raloxifene HydrochlorideERBB2 protein results in decreased susceptibility to Raloxifene Hydrochloride16609042
D012110ReserpineERBB2 protein results in increased susceptibility to Reserpine8093862
C059514resveratrol[Coumestrol co-treated with resveratrol] results in decreased expression of ERBB2 mRNA19167446
C059514resveratrolEGF protein inhibits the reaction [resveratrol results in decreased phosphorylation of ERBB2 protein]20729295
C059514resveratrolEstradiol promotes the reaction [resveratrol results in increased expression of ERBB2 protein]16488535
C059514resveratrolresveratrol results in decreased expression of ERBB215688416
C059514resveratrolresveratrol results in decreased expression of ERBB2 mRNA25448084
C059514resveratrolresveratrol results in decreased expression of ERBB2 protein16488535|2544808
C059514resveratrolresveratrol results in decreased phosphorylation of ERBB2 protein20729295
C059514resveratrolresveratrol results in increased expression of ERBB2 mRNA16488535
C059514resveratrolresveratrol results in increased expression of ERBB2 protein16488535
C059514resveratrolresveratrol results in decreased expression of ERBB215688416
C020491rheinrhein results in decreased expression of ERBB2 protein21457705
D018967RisperidoneRisperidone results in increased phosphorylation of ERBB2 protein26961615
C087123romidepsinromidepsin results in decreased expression of ERBB2 protein15014036
C090142secoisolariciresinol diglucosidesecoisolariciresinol diglucoside results in decreased expression of ERBB2 protein19904759
C090142secoisolariciresinol diglucosidesecoisolariciresinol diglucoside results in decreased phosphorylation of ERBB2 protein19904759
D012643Selenium[Selenium co-treated with Vitamin E] results in increased expression of ERBB2 mRNA19244175
D012643SeleniumSelenium results in increased expression of ERBB2 mRNA19244175
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of ERBB2 mRNA25895662
C017947sodium arseniteERBB2 mutant form inhibits the reaction [sodium arsenite results in increased expression of CDKN1A protein]15734884
C017947sodium arsenitesodium arsenite affects the expression of ERBB2 protein17384772
C017947sodium arsenitesodium arsenite results in increased phosphorylation of and results in increased activity of ERBB2 protein15734884
C017947sodium arsenitesodium arsenite results in increased phosphorylation of ERBB2 protein20043101
C017947sodium arsenitetyrphostin AG825 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of ERBB2 protein]15734884
C017947sodium arsenitesodium arsenite results in increased expression of ERBB2 mRNA11241755
C025462sulindac sulfidebenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of ERBB2 protein]20332299
C025462sulindac sulfidesulindac sulfide results in decreased expression of ERBB2 protein20332299
C025463sulindac sulfonesulindac sulfone results in decreased expression of ERBB2 protein20332299
D013629TamoxifenERBB2 protein inhibits the reaction [PA2G4 protein results in increased susceptibility to Tamoxifen]20379846
D013629TamoxifenERBB2 protein results in decreased susceptibility to Tamoxifen15665275|1600058
D013629Tamoxifen[ERBB2 protein results in increased activity of ESR1 protein] which results in decreased susceptibility to Tamoxifen20179226
D013629TamoxifenTamoxifen results in increased phosphorylation of ERBB2 protein17157789
D013629TamoxifenTamoxifen results in increased expression of ERBB2 protein21138602
D013629TamoxifenTamoxifen results in increased phosphorylation of ERBB2 protein21138602
C112765tanespimycintanespimycin results in increased degradation of and results in decreased expression of ERBB2 protein16061882
C020806tetrabromobisphenol Atetrabromobisphenol A results in increased expression of ERBB2 mRNA26353976
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of ERBB2 mRNA22298810|2257421
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of ERBB2 mRNA26238291
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of ERBB2 mRNA11162886|1755586
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin promotes the reaction [AHR protein binds to ERBB2 promoter]19654925
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of ERBB2 mRNA21215274
C005806tetrachloroisophthalonitriletetrachloroisophthalonitrile results in increased activity of ERBB2 protein11222871
D013755Tetradecanoylphorbol AcetatePIN1 protein promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of ERBB2 protein]20479004
D013755Tetradecanoylphorbol AcetateTetradecanoylphorbol Acetate results in increased expression of ERBB2 protein20479004
D013792Thalidomide[ERBB2 protein co-treated with PIK3CA protein mutant form] results in increased susceptibility to Thalidomide metabolite28745489
D013852ThiotepaERBB2 protein affects the susceptibility to Thiotepa10327070
D013852ThiotepaERBB2 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Thiotepa co-treated with Carboplatin]16446318
C009495titanium dioxidetitanium dioxide results in decreased expression of ERBB2 mRNA23409001
D014212TretinoinTretinoin results in decreased expression of ERBB2 mRNA21934132
D014212TretinoinTretinoin results in decreased expression of ERBB2 protein16752155
D014212TretinoinHBEGF protein promotes the reaction [Tretinoin results in increased phosphorylation of ERBB2 protein]16357442
D014212TretinoinTretinoin results in increased phosphorylation of ERBB2 protein16357442
D014241TrichloroethyleneTrichloroethylene results in decreased expression of ERBB2 mRNA15363585
C015559trimellitic anhydridetrimellitic anhydride results in decreased expression of ERBB2 mRNA19042947
C101044tyrphostin AG 1478[tyrphostin AG 1478 co-treated with AG-879] results in decreased phosphorylation of ERBB2 protein18618485
C098214tyrphostin AG825tyrphostin AG825 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of ERBB2 protein]15734884
C098214tyrphostin AG825tyrphostin AG825 results in decreased activity of and results in decreased phosphorylation of ERBB2 protein20058253
C098214tyrphostin AG825tyrphostin AG825 results in decreased activity of ERBB2 protein15254267
C022884undecaneundecane results in decreased expression of ERBB2 protein17337753
D014520UrethaneUrethane results in decreased expression of ERBB2 mRNA28818685
D014635Valproic AcidValproic Acid affects the expression of ERBB2 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of ERBB2 mRNA23179753|2800136
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of ERBB2 gene25560391
D014747VinblastineERBB2 protein affects the susceptibility to Vinblastine10327070
C025643vinclozolin[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA25607892
D014810Vitamin E[Selenium co-treated with Vitamin E] results in increased expression of ERBB2 mRNA19244175
C111237vorinostatvorinostat results in decreased expression of ERBB2 mRNA27188386
C111237vorinostatvorinostat results in decreased expression of ERBB2 protein17218635
C111237vorinostatvorinostat results in increased ubiquitination of and results in increased degradation of and results in decreased expression of ERBB2 protein16144943

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0001042RNA polymerase I core binding-IDA21555369  
GO:0004709MAP kinase kinase kinase activity-IBA21873635  
GO:0004713protein tyrosine kinase activity-IBA21873635  
GO:0004713protein tyrosine kinase activity-IDA7556068  
GO:0004713protein tyrosine kinase activity-IGI7556068  
GO:0004713protein tyrosine kinase activity-TAS-  
GO:0004714transmembrane receptor protein tyrosine kinase activity-IBA21873635  
GO:0004714transmembrane receptor protein tyrosine kinase activity-IDA7514177  
GO:0004888transmembrane signaling receptor activity-IBA21873635  
GO:0004888transmembrane signaling receptor activity-IDA7514177  
GO:0005088Ras guanyl-nucleotide exchange factor activity-TAS-  
GO:0005515protein binding-IPI7592681  9079677  9705354  10572067  10805725  11067847  
11940572  12061724  12122014  12975581  15657067  16273093  
16314522  16516204  16729043  16767099  16843263  17148612  
17426253  18719096  19167335  19372587  19411071  19650109  
19933325  20010870  20227043  20558745  20700126  20876300  
21034468  21075308  21203579  21255571  21278786  21376233  
21555369  21724847  21840311  22279592  22589551  22733765  
22806884  22939624  23436906  23680147  23688700  23866081  
23995768  24189400  24412244  24557338  24658140  24815698  
25036637  25081058  25241761  25326665  25640309  26517842  
GO:0005524ATP binding-IEA-  
GO:0008022protein C-terminus binding-IPI15520177  
GO:0019838growth factor bindingcontributes_toIDA7514177  
GO:0019903protein phosphatase binding-IPI15899872  
GO:0031434mitogen-activated protein kinase kinase binding-IBA21873635  
GO:0042802identical protein binding-IPI16843263  17148612  19650109  21203579  21255571  21480528  
22733765  23436906  
GO:0043125ErbB-3 class receptor binding-TAS9590694  
GO:0046934phosphatidylinositol-4,5-bisphosphate 3-kinase activity-TAS-  
GO:0046982protein heterodimerization activity-IDA10572067  
GO:0046982protein heterodimerization activity-IPI7556068  
GO:0046983protein dimerization activity-NAS12000754  
GO ID GO Term Qualifier Evidence PubMed
GO:0000165MAPK cascade-TAS-  
GO:0001934positive regulation of protein phosphorylation-ISS-  
GO:0006351transcription, DNA-templated-IEA-  
GO:0006357regulation of transcription by RNA polymerase II-TAS-  
GO:0006468protein phosphorylation-TAS10851066  
GO:0007165signal transduction-IDA10572067  
GO:0007166cell surface receptor signaling pathway-IDA9685399  
GO:0007167enzyme linked receptor protein signaling pathway-TAS9590694  
GO:0007169transmembrane receptor protein tyrosine kinase signaling pathway-IDA7514177  
GO:0007169transmembrane receptor protein tyrosine kinase signaling pathway-TAS7556068  
GO:0007275multicellular organism development-IBA21873635  
GO:0007422peripheral nervous system development-IEA-  
GO:0007507heart development-IEA-  
GO:0007528neuromuscular junction development-IEA-  
GO:0008045motor neuron axon guidance-IEA-  
GO:0008283cell proliferation-TAS10851066  
GO:0009968negative regulation of signal transduction-IBA21873635  
GO:0014065phosphatidylinositol 3-kinase signaling-IDA7556068  
GO:0018108peptidyl-tyrosine phosphorylation-IEA-  
GO:0030154cell differentiation-IBA21873635  
GO:0030307positive regulation of cell growth-IMP21555369  
GO:0032886regulation of microtubule-based process-IDA20937854  
GO:0033088negative regulation of immature T cell proliferation in thymus-IEA-  
GO:0033674positive regulation of kinase activity-IBA21873635  
GO:0038128ERBB2 signaling pathway-TAS-  
GO:0042060wound healing-IDA12646923  
GO:0042552myelination-IEA-  
GO:0043066negative regulation of apoptotic process-IBA21873635  
GO:0043406positive regulation of MAP kinase activity-IDA10572067  
GO:0043410positive regulation of MAPK cascade-IBA21873635  
GO:0043547positive regulation of GTPase activity-ISS-  
GO:0045727positive regulation of translation-IMP21555369  
GO:0045765regulation of angiogenesis-NAS15609325  
GO:0045785positive regulation of cell adhesion-IDA7556068  
GO:0045943positive regulation of transcription by RNA polymerase I-IMP21555369  
GO:0045945positive regulation of transcription by RNA polymerase III-IDA19372587  
GO:0046777protein autophosphorylation-IDA7556068  
GO:0046854phosphatidylinositol phosphorylation-IEA-  
GO:0048709oligodendrocyte differentiation-IEA-  
GO:0050679positive regulation of epithelial cell proliferation-IDA10572067  
GO:0051897positive regulation of protein kinase B signaling-TAS-  
GO:0070372regulation of ERK1 and ERK2 cascade-IMP16314522  
GO:0070374positive regulation of ERK1 and ERK2 cascade-IBA21873635  
GO:0071363cellular response to growth factor stimulus-IDA20010870  
GO:0071364cellular response to epidermal growth factor stimulus-IMP27134172  
GO:0090314positive regulation of protein targeting to membrane-IDA20010870  
GO:1901185negative regulation of ERBB signaling pathway-TAS-  
GO:2000145regulation of cell motility-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IDA16314522  21555369  
GO:0005737cytoplasm-IBA21873635  
GO:0005829cytosol-IDA-  
GO:0005886plasma membrane-IDA20010870  
GO:0005886plasma membrane-NAS12000754  
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-IBA21873635  
GO:0009925basal plasma membrane-IBA21873635  
GO:0010008endosome membrane-IDA16314522  
GO:0016021integral component of membrane-NAS15609325  
GO:0016323basolateral plasma membrane-IDA12646923  
GO:0016324apical plasma membrane-IEA-  
GO:0043209myelin sheath-IEA-  
GO:0043235receptor complex-IBA21873635  
GO:0043235receptor complex-IDA7514177  23382219  
GO:0043235receptor complex-TAS7556068  
GO:0048471perinuclear region of cytoplasm-IEA-  
KEGG ID KEGG Term
hsa04012ErbB signaling pathway
hsa04020Calcium signaling pathway
hsa04510Focal adhesion
hsa04520Adherens junction
hsa05200Pathways in cancer
hsa05212Pancreatic cancer
hsa05213Endometrial cancer
hsa05215Prostate cancer
hsa05219Bladder cancer
hsa05223Non-small cell lung cancer
Reactome ID Reactome Term Evidence
R-HSA-1227986Signaling by ERBB2TAS
R-HSA-1227986Signaling by ERBB2IEA
R-HSA-1250196SHC1 events in ERBB2 signalingIEA
R-HSA-1250196SHC1 events in ERBB2 signalingTAS
R-HSA-1251932PLCG1 events in ERBB2 signalingIEA
R-HSA-1257604PIP3 activates AKT signalingTAS
R-HSA-1266738Developmental BiologyTAS
R-HSA-1306955GRB7 events in ERBB2 signalingTAS
R-HSA-1358803Downregulation of ERBB2:ERBB3 signalingTAS
R-HSA-162582Signal TransductionTAS
R-HSA-162582Signal TransductionIEA
R-HSA-1643685DiseaseTAS
R-HSA-1963640GRB2 events in ERBB2 signalingIEA
R-HSA-1963640GRB2 events in ERBB2 signalingTAS
R-HSA-1963642PI3K events in ERBB2 signalingTAS
R-HSA-199418Negative regulation of the PI3K/AKT networkTAS
R-HSA-212436Generic Transcription PathwayTAS
R-HSA-2219528PI3K/AKT Signaling in CancerTAS
R-HSA-2219530Constitutive Signaling by Aberrant PI3K in CancerTAS
R-HSA-373755Semaphorin interactionsTAS
R-HSA-400685Sema4D in semaphorin signalingTAS
R-HSA-416572Sema4D induced cell migration and growth-cone collapseTAS
R-HSA-422475Axon guidanceTAS
R-HSA-5663202Diseases of signal transductionTAS
R-HSA-5673001RAF/MAP kinase cascadeTAS
R-HSA-5683057MAPK family signaling cascadesTAS
R-HSA-5684996MAPK1/MAPK3 signalingTAS
R-HSA-6785631ERBB2 Regulates Cell MotilityTAS
R-HSA-6811558PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingTAS
R-HSA-73857RNA Polymerase II TranscriptionTAS
R-HSA-74160Gene expression (Transcription)TAS
R-HSA-8847993ERBB2 Activates PTK6 SignalingTAS
R-HSA-8848021Signaling by PTK6TAS
R-HSA-8863795Downregulation of ERBB2 signalingTAS
R-HSA-8864260Transcriptional regulation by the AP-2 (TFAP2) family of transcription factorsTAS
R-HSA-8866910TFAP2 (AP-2) family regulates transcription of growth factors and their receptorsTAS
R-HSA-9006925Intracellular signaling by second messengersTAS
R-HSA-9006927Signaling by Non-Receptor Tyrosine KinasesTAS
R-HSA-9006934Signaling by Receptor Tyrosine KinasesTAS
R-HSA-9006934Signaling by Receptor Tyrosine KinasesIEA

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
27262212Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis. (2016 Aug)Noonan SAJ Thorac Oncol
17164260Effect of ATM, CHEK2 and ERBB2 TAGSNPs and haplotypes on endometrial cancer risk. (2007 Jan 15)Einarsdottir KHum Mol Genet
21455582Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. (2011 Jun)Santini DOncol Rep
21316260Targeting phosphoinositide 3-kinase signalling in lung cancer. (2011 Nov)Wojtalla ACrit Rev Oncol Hematol
20832392MUC1 expression and its association with other aetiological factors and localization to mitochondria in preneoplastic and neoplastic gastric tissues. (2010 Dec 14)Benjamin JBClin Chim Acta
25351745MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. (2015 Apr 15)Arcila MEClin Cancer Res
29511884Podoplanin-positive cancer-associated fibroblast recruitment within cancer stroma is associated with a higher number of single nucleotide variants in cancer cells in lung adenocarcinoma. (2018 May)Nakasone SJ Cancer Res Clin Oncol
23744164The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy. (2013)Nicos MPneumonol Alergol Pol
9445135Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients. (1998 Jan)Fleming MVHum Pathol
28753770Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers. (2016 Jun 24)Joshi MEur Urol Focus
16003726EGFR and erbB2 mutation status in Japanese lung cancer patients. (2006 Jan 1)Sasaki HInt J Cancer
24137397Keap1 mutations in lung cancer patients. (2013 Sep)Sasaki HOncol Lett
26200269Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. (2015 Aug)Shim HSJ Thorac Oncol
25738220Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. (2015 May)Sholl LMJ Thorac Oncol
23723294Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). (2013 Sep)Dearden SAnn Oncol
14581353Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. (2003 Oct 15)Miller CTClin Cancer Res
26873401Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population. (2016 May)Sawada GGastroenterology
23991993B-cell Lymphoma 2 rs17757541 C>G polymorphism was associated with an increased risk of gastric cardiac adenocarcinoma in a Chinese population. (2013)Li QAsian Pac J Cancer Prev
28472989Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. (2017 May 4)Yang MJ Hematol Oncol
28169993The evolving genomic landscape of urothelial carcinoma. (2017 Feb 7)Glaser APNat Rev Urol
23303019Expression of Epidermal Growth Factor (EGF) and its receptors (EGFR1 and EGFR2) in chronic bronchitis. (2012)Marinas AERom J Morphol Embryol
19046792Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas. (2009 Jul)Lopez-Malpartida AVLung Cancer
27939360Cellular and molecular mechanisms underlying alcohol-induced aggressiveness of breast cancer. (2017 Jan)Wang YPharmacol Res
20604875ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas. (2010 Nov)Silva SDOral Dis
27565922Hot spot mutations in Finnish non-small cell lung cancers. (2016 Sep)Maki-Nevala SLung Cancer
19690778Malignant fibrous histiocytoma of larynx with giant cell: case report and histological-clinical considerations. (2009)Anghelina FRom J Morphol Embryol
15563701Expression of ErbB receptors and mucins in the airways of long term current smokers. (2004 Dec)O'Donnell RAThorax
25007143Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. (2014 Dec)Boland JMAm J Surg Pathol
24278325Distinct effects of alcohol consumption and smoking on genetic alterations in head and neck carcinoma. (2013)Urashima MPLoS One
19690148Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice. (2009 Sep 1)Ohashi KCancer Res
16865253Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy. (2006 Sep)Endo KOncol Rep
24137465Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non-small cell lung cancer to the central nervous system. (2013 Oct)Krawczyk POncol Lett
25567908Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. (2015 Aug 15)Drilon AClin Cancer Res
29217530The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). (2018 Mar 1)Aisner DLClin Cancer Res
22969966Braf and erbB2 mutations correlate with smoking status in lung cancer patients. (2012 May)Sasaki HExp Ther Med